WO2020207165A1 - 治疗脉管畸形的化合物 - Google Patents

治疗脉管畸形的化合物 Download PDF

Info

Publication number
WO2020207165A1
WO2020207165A1 PCT/CN2020/078296 CN2020078296W WO2020207165A1 WO 2020207165 A1 WO2020207165 A1 WO 2020207165A1 CN 2020078296 W CN2020078296 W CN 2020078296W WO 2020207165 A1 WO2020207165 A1 WO 2020207165A1
Authority
WO
WIPO (PCT)
Prior art keywords
vascular
ddx24
cysltr1
montelukast sodium
antagonist
Prior art date
Application number
PCT/CN2020/078296
Other languages
English (en)
French (fr)
Inventor
单鸿
庞鹏飞
毛军杰
胡晓俊
何欢欢
肖非
Original Assignee
中山大学附属第五医院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中山大学附属第五医院 filed Critical 中山大学附属第五医院
Publication of WO2020207165A1 publication Critical patent/WO2020207165A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • the present invention relates to new applications of compounds and methods for the treatment of diseases, in particular to compounds and methods for the treatment of vascular malformations.
  • the vasculature is mainly composed of blood vessels and lymphatic vessels, which undertake important physiological functions of the human body.
  • Vascular diseases refer to abnormal proliferation, communication or morphological changes of the vascular system caused by various factors.
  • Vascular diseases can occur in any tissue and part of the human body, and often exhibit aggressive and even malignant growth characteristics, which are extremely harmful to health.
  • Vascular diseases that occur in the limbs, body surface, or face, in addition to affecting aesthetics can also form irregular boundaries, oppress or invade adjacent tissues and organs, and cause the loss of normal physiological functions in severe cases.
  • High-velocity vascular disease can lead to heart failure due to hemodynamic disturbances.
  • Some vascular diseases are prone to bleeding due to the abnormal structure of the tube wall. Severe visceral bleeding or intracranial bleeding can endanger the life of the patient.
  • vascular diseases are often congenital. According to the literature, the incidence of vascular diseases in the population is about 1.5%, of which 2/3 mainly involve veins. Because vascular diseases in superficial parts are easy to detect, patients can often get early diagnosis and treatment, and the clinical effect is acceptable. The lesions of deep tissues rely on imaging examinations, such as ultrasound, CT, MRI, digital subtraction angiography, DSA, etc., which are often missed or even misdiagnosed in clinical diagnosis and treatment. Patients often wait until serious complications occur before being diagnosed and treated. If they miss the opportunity for early treatment, the prognosis is often poor.
  • the main treatment methods for vascular diseases include surgical resection, isotope therapy, laser therapy, interventional embolization and sclerotherapy. However, the above treatment methods are all symptomatic treatments, and they cannot cure vascular diseases from the etiology.
  • the inventor discovered a family of hereditary vascular diseases on the basis of four previous studies. The etiology is unclear. The main clinical manifestations involve the portal vein, hepatic vein, pulmonary valve, and lymphatic system; through clinical diagnosis and literature review, it is clear The disease in this family is a brand-new syndrome, named multiple organ venous-lymphatic malformation syndrome; through genetic screening, it is determined that the DDX24 gene mutation is the causative gene of the syndrome; through cell experiments, zebrafish knockout In addition to the experimental confirmation that DDX24 is an important gene for vascular development; at the same time, among the 151 congenital sporadic cases with hepatic vein stenosis as the clinical feature, 26 patients have DDX24 gene mutations; verify that DDX24 mutations are the cause of vascular diseases Important pathogenic factors.
  • DDX24 gene mutation is an important pathogenic gene of vascular malformations (Pang P, Hu X, Zhou B, et al. DDX 24 Mutations Associated with Malformations of Major Vessels to the Viscera [J]. Hepatology, 2018.).
  • CN108018296A discloses DDX24 gene mutations and their applications.
  • DDX24 gene SNP mutations include Glu271Lys, Lys11Glu and Arg436His.
  • the mutations Glu271Lys, Lys11Glu or Arg436His of DDX24 are significantly related to the development of vasculature. By interfering with DDX24, it can promote cell migration and vascular formation, leading to vascular malformations.
  • By detecting the SNP sites of DDX24 it can effectively predict the occurrence of vascular malformations in the human body, and can be used for screening of genetic defects. At the same time, it helps to correctly judge the type of abnormal vascular diseases, reduce misdiagnosis, and facilitate targeted treatment.
  • CysLTs are lipid inflammatory mediators that work by binding to the receptor CysLTR1 or CysLTR2, and CysLTR1 is a receptor sensitive to classical receptor antagonists. CysLTR1 is normally expressed in peripheral blood leukocytes and bronchial smooth muscle cells. The inflammatory environment can up-regulate the expression of CysLTR1 in lesions, mediate tissue damage in the acute phase and tissue proliferation changes in the chronic phase of inflammatory lesions, and participate in atherosclerosis, aneurysm, The occurrence and development of chronic diseases such as cirrhosis and portal hypertension.
  • CysLTR1 is montelukast sodium (trade name: Shun Erning).
  • CysLTR1 antagonists include Zafirlukast (DB00549), Cinalukast (DB00587), Nedocromil (DB00716), Prannukast (DB01411), see https://www.drugbank.ca.
  • the purpose of the present invention is to provide an effective method for treating or alleviating vascular malformations.
  • CysLTR1 antagonist in preparing medicine for treating vascular malformation.
  • vascular malformations are those caused by abnormal expression of DDX24.
  • vascular malformations include portal vein stenosis, hepatic vein stenosis, pulmonary valve stenosis, chylothorax, portal hypertension, MOVLD syndrome, idiopathic non-sclerosing portal hypertension signs.
  • the CysLTR1 antagonist is selected from montelukast sodium, Zafirlukast, Cinalukast, Nedocromil, Pranlukast, and pharmaceutically acceptable derivatives thereof.
  • a method for treating vascular malformations includes administering an effective therapeutic amount of CysLTR1 antagonist to the patient.
  • vascular malformations are those caused by abnormal expression of DDX24.
  • vascular malformations include portal vein stenosis, hepatic vein stenosis, pulmonary valve stenosis, chylothorax, portal hypertension, MOVLD syndrome, idiopathic non-sclerosing portal hypertension signs.
  • the CysLTR1 antagonist is selected from montelukast sodium, Zafirlukast, Cinalukast, Nedocromil, Pranlukast, and pharmaceutically acceptable derivatives thereof.
  • CysLTR1 antagonist as a drug for the treatment of vascular malformations.
  • vascular malformations are those caused by abnormal expression of DDX24.
  • vascular malformations include portal vein stenosis, hepatic vein stenosis, pulmonary valve stenosis, chylothorax, portal hypertension, MOVLD syndrome, idiopathic non-sclerosing portal hypertension signs.
  • the CysLTR1 antagonist is selected from montelukast sodium, Zafirlukast, Cinalukast, Nedocromil, Pranlukast, and pharmaceutically acceptable derivatives thereof.
  • CysLTR1 antagonists such as montelukast sodium, can up-regulate the expression of DDX24 in vascular smooth muscle cells and have a certain therapeutic or ameliorating effect on vascular malformations.
  • Figure 1 shows the effect of CysLTR1 antagonist on the growth of human lymphatic endothelial cells
  • Figure 2 is the result of qPCR experiment of DDX24 mRNA in human lymphatic endothelial cells
  • Figure 3 is the result of qPCR experiment of DDX24 mRNA in human umbilical vein endothelial cells
  • Figure 4 is the experimental result of the effect of montelukast sodium on the expression of DDX24 protein
  • Figure 5 shows the effect of different CysLTR1 antagonists on the ATPase activity of DDX24
  • Figure 6 is a CT diagram of the therapeutic effect of different treatment schemes on patients with visceral vascular malformations.
  • CysLTR1 antagonist in preparing medicine for treating vascular malformation.
  • vascular malformations are those caused by abnormal expression of DDX24.
  • vascular malformations include portal vein stenosis, hepatic vein stenosis, pulmonary valve stenosis, chylothorax, portal hypertension, MOVLD syndrome, idiopathic non-sclerosing portal hypertension signs.
  • the CysLTR1 antagonist is selected from montelukast sodium, Zafirlukast, Cinalukast, Nedocromil, Pranlukast, and pharmaceutically acceptable derivatives thereof.
  • a method for treating vascular malformations includes administering an effective therapeutic amount of CysLTR1 antagonist to the patient.
  • vascular malformations are those caused by abnormal expression of DDX24.
  • vascular malformations include portal vein stenosis, hepatic vein stenosis, pulmonary valve stenosis, chylothorax, portal hypertension, MOVLD syndrome, idiopathic non-sclerosing portal hypertension signs.
  • the CysLTR1 antagonist is selected from montelukast sodium, Zafirlukast, Cinalukast, Nedocromil, Pranlukast, and pharmaceutically acceptable derivatives thereof.
  • CysLTR1 antagonist as a drug for the treatment of vascular malformations.
  • vascular malformations are those caused by abnormal expression of DDX24.
  • vascular malformations include portal vein stenosis, hepatic vein stenosis, pulmonary valve stenosis, chylothorax, portal hypertension, MOVLD syndrome, idiopathic non-sclerosing portal hypertension signs.
  • the CysLTR1 antagonist is selected from montelukast sodium, Zafirlukast, Cinalukast, Nedocromil, Pranlukast, and pharmaceutically acceptable derivatives thereof.
  • the pharmaceutically acceptable derivatives of montelukast sodium especially include the compounds claimed in the claims of its original patent US4918081.
  • Figure 2 shows the results of qPCR experiments of DDX24 mRNA in human lymphatic endothelial cells.
  • Con is a negative control and MS is Shun Erning. *Represents p ⁇ 0.05. It can be seen from the figure that Shun Erning can increase the mRNA level of DDX24 in human lymphatic endothelial cells.
  • Figure 3 shows the results of qPCR experiments of DDX24 mRNA in human umbilical vein endothelial cells.
  • Con is a negative control and MS is Shun Erning.
  • the inventor added montelukast sodium and its similar compounds Pranlukast and Zallukast into vascular endothelial cells, and the ATPase activity detection experiment showed that montelukast sodium and its similar compounds Prankast and Zallukast It specifically inhibits the ATPase activity of DDX24.
  • the results of the experiment are shown in Figure 5.
  • Con is the negative control
  • MS is Shun Erning
  • Pra Prankast
  • Zaf Zalust.
  • the results show that montelukast sodium and its similar compounds have a weak inhibitory effect on the ATPase activity of DDX24
  • CT showed obvious absorption of thoracic and ascites fluid, no obvious abnormality in the ratio of left and right lobe liver, lower extremity edema and shortness of breath were obviously relieved; after the recent montelukast sodium treatment, the patient's abdominal distension and shortness of breath were significantly relieved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

公开了治疗脉管畸形的化合物。研究发现，CysLTRI拮抗剂可以上调血管平滑肌细胞DDX24中的表达，对脉管畸形具有一定的治疗或改善效果。

Description

治疗脉管畸形的化合物 技术领域
本发明涉及化合物的新应用及疾病的治疗方法，特别涉及治疗脉管畸形的化合物及方法。
背景技术
脉管系统主要由血管和淋巴管组成，承担人体重要的生理功能。脉管疾病是指各种因素所导致的脉管系统异常增生、沟通或形态改变。脉管疾病可发生于人体任何组织和部位，经常表现出侵袭性，甚至恶性生长的特性，对健康危害极大。发生于四肢、体表或颜面部的脉管疾病除影响美观外，还可形成边界不规则的占位，压迫或侵犯邻近的组织和器官，严重者导致正常生理功能的丧失。高流速型脉管疾病因血流动力学的紊乱可导致心功能衰竭。部分脉管疾病因管壁结构组织的异常极易发生出血，严重的内脏出血或颅内出血均可危及患者生命。
脉管疾病往往为先天性的，文献报道脉管疾病在人群中的发生率约为1.5％，其中2/3主要累及静脉。浅表部位的脉管疾病由于易于发现，患者往往能够得到早期诊断和治疗，临床疗效尚可。而深部组织的病变则有赖于影像学检查，如超声、CT、MRI、数字减影血管造影DSA等，在临床诊疗中经常漏诊，甚至误诊。患者经常是等到发生了严重的并发症时才得到诊治，错过了早期治疗时机，预后往往不良。目前，针对脉管疾病的治疗手段主要有手术切除、同位素疗法、激光疗法、介入栓塞及硬化治疗等。然而，以上治疗手段均属于对症治疗，都不能从病因上对脉管性疾病进行根治。
发明人在经过四年前期研究的基础上发现了一个遗传性脉管疾病家系，其病因不清，临床主要表现累及门静脉、肝静脉、肺动脉瓣、淋巴管系统；通过临床诊断及查阅文献，明确该家系所患疾病为一个全新的综合征，并命名为多器官静脉-淋巴管畸形综合征；通过基因筛查，确定DDX24基因突变为该综合征的致病基因；通过细胞实验、斑马鱼敲除实验证实DDX24是脉管发育的重要基因；同时在主要以肝静脉狭窄为临床特征的151例先天性脉管散发病例中，26例患者存在DDX24基因突变；验证DDX24突变是脉管性疾病的重要致病因素。前期研究表明DDX24基因突变是脉管畸形的重要致病基因(Pang P,Hu X,Zhou B,et al.DDX 24 Mutations Associated with Malformations of Major Vessels to the Viscera[J].Hepatology,2018.)。
CN108018296A公开了DDX24基因突变及其应用，DDX24基因SNP突变，包括Glu271Lys、 Lys11Glu、Arg436His。DDX24的突变Glu271Lys、Lys11Glu或Arg436His与脉管的发育有着显著的关联性。通过干扰DDX24，可以促进细胞迁移和脉管形成，导致脉管畸形的发生。通过检测DDX24的SNP位点，可以有效地预测人体的脉管畸形发生情况，可以用于遗传缺陷的筛查，同时有助于正确判断脉管异常疾病的类型，减少误诊，方便针对性治疗。
然而，现有技术中并没有有效治疗脉管畸形的方法。
半胱氨酰白三烯(The cysteinyl leukotrienes，CysLTs)是脂质类炎症介质，通过与受体CysLTR1或CysLTR2结合发挥作用，其中CysLTR1为对经典受体拮抗剂敏感的受体。CysLTR1正常情况下主要表达于外周血白细胞和支气管平滑肌细胞，炎症环境可上调病变部位CysLTR1表达，介导炎症病灶急性期组织损伤和慢性期组织增生性改变，并参与动脉粥样硬化、动脉瘤、肝硬化门静脉高压等慢性疾病的发生发展。因为肿瘤组织同样提供了炎性环境，可导致肿瘤组织中CysLTR1表达上调，与肿瘤转化密切相关。目前CysLTR1的主要拮抗剂为孟鲁司特钠(商品名：顺尔宁)。其他的CysLTR1拮抗剂包括Zafirlukast(DB00549)、Cinalukast(DB00587)、Nedocromil(DB00716)、Pranlukast(DB01411)，参见https://www.drugbank.ca。
发明内容
本发明的目的在于提供一种有效治疗或缓解脉管畸形的方法。
本发明所采取的技术方案是：
CysLTR1拮抗剂在制备治疗脉管畸形药物中的应用。
在一些实例中，脉管畸形为DDX24异常表达引起的脉管畸形。
在一些实例中，脉管畸形包括门静脉狭窄、肝静脉狭窄、肺动脉瓣狭窄、乳糜胸、门脉高压、MOVLD综合征、特发性非硬化性门脉高压征。
在一些实例中，CysLTR1拮抗剂选自孟鲁司特钠、Zafirlukast、Cinalukast、Nedocromil、Pranlukast及其药学上可接受的衍生物。
一种治疗脉管畸形的方法，包括给予病人有效治疗量的CysLTR1拮抗剂。
在一些实例中，脉管畸形为DDX24异常表达引起的脉管畸形。
在一些实例中，脉管畸形包括门静脉狭窄、肝静脉狭窄、肺动脉瓣狭窄、乳糜胸、门脉高压、MOVLD综合征、特发性非硬化性门脉高压征。
在一些实例中，CysLTR1拮抗剂选自孟鲁司特钠、Zafirlukast、Cinalukast、Nedocromil、Pranlukast及其药学上可接受的衍生物。
作为治疗脉管畸形药物的CysLTR1拮抗剂。
在一些实例中，脉管畸形为DDX24异常表达引起的脉管畸形。
在一些实例中，脉管畸形包括门静脉狭窄、肝静脉狭窄、肺动脉瓣狭窄、乳糜胸、门脉高压、MOVLD综合征、特发性非硬化性门脉高压征。
在一些实例中，CysLTR1拮抗剂选自孟鲁司特钠、Zafirlukast、Cinalukast、Nedocromil、Pranlukast及其药学上可接受的衍生物。
本发明的有益效果是：
发明人研究发现，CysLTR1拮抗剂，如孟鲁司特钠可以上调血管平滑肌细胞DDX24中的表达，对脉管畸形具有一定的治疗或改善效果。
附图说明
图1是CysLTR1拮抗剂对人淋巴管内皮细胞生长的影响；
图2是人淋巴内皮细胞中DDX24的mRNA的qPCR实验结果；
图3是人脐静脉内皮细胞中DDX24的mRNA的qPCR实验结果；
图4是孟鲁司特钠对DDX24蛋白表达影响的实验结果；
图5是不同CysLTR1拮抗剂对DDX24的ATPase酶活性的影响；
图6是不同治疗方案对内脏脉管畸形患者的治疗效果CT图。
具体实施方式
CysLTR1拮抗剂在制备治疗脉管畸形药物中的应用。
在一些实例中，脉管畸形为DDX24异常表达引起的脉管畸形。
在一些实例中，脉管畸形包括门静脉狭窄、肝静脉狭窄、肺动脉瓣狭窄、乳糜胸、门脉高压、MOVLD综合征、特发性非硬化性门脉高压征。
在一些实例中，CysLTR1拮抗剂选自孟鲁司特钠、Zafirlukast、Cinalukast、Nedocromil、Pranlukast及其药学上可接受的衍生物。
一种治疗脉管畸形的方法，包括给予病人有效治疗量的CysLTR1拮抗剂。
在一些实例中，脉管畸形为DDX24异常表达引起的脉管畸形。
在一些实例中，脉管畸形包括门静脉狭窄、肝静脉狭窄、肺动脉瓣狭窄、乳糜胸、门脉高压、MOVLD综合征、特发性非硬化性门脉高压征。
在一些实例中，CysLTR1拮抗剂选自孟鲁司特钠、Zafirlukast、Cinalukast、Nedocromil、Pranlukast及其药学上可接受的衍生物。
作为治疗脉管畸形药物的CysLTR1拮抗剂。
在一些实例中，脉管畸形为DDX24异常表达引起的脉管畸形。
在一些实例中，脉管畸形包括门静脉狭窄、肝静脉狭窄、肺动脉瓣狭窄、乳糜胸、门脉高压、MOVLD综合征、特发性非硬化性门脉高压征。
在一些实例中，CysLTR1拮抗剂选自孟鲁司特钠、Zafirlukast、Cinalukast、Nedocromil、Pranlukast及其药学上可接受的衍生物。
孟鲁司特钠药学上可接受的衍生物，特别包括其原研专利US4918081权利要求所请求保护的化合物。
下面结合实验，进一步说明本发明的技术方案。
CysLTR1拮抗剂对人淋巴管内皮细胞生长的影响
发明人在前期的实验过程，将孟鲁司特钠添加人淋巴管内皮细胞中，通过细胞活性实验发现，孟鲁司特钠抑制人淋巴管内皮细胞的生长，其半数抑制浓度约为36.9μM。实验结果如图1所示。
CysLTR1拮抗剂对DDX24表达的影响
发明人在前期的实验过程，将孟鲁司特钠添加血管内皮细胞中，通过RT-PCR检测发现，孟鲁司特钠可以上调脐静脉内皮细胞及人淋巴管内皮细胞中DDX24的表达(与对照比较<0.05)。实验结果如图2和图3所示。
其中：
图2为人淋巴内皮细胞中DDX24的mRNA的qPCR实验结果，图中，Con为阴性对照，MS为顺尔宁。*代表p<0.05。从图中可以看出，顺尔宁可以提高人淋巴内皮细胞中DDX24的mRNA水平。
图3为人脐静脉内皮细胞中DDX24的mRNA的qPCR实验结果，图中，Con为阴性对照，MS为顺尔宁。*代表p<0.05，***代表p<0.001。
在过表达DDX24荧光素酶报告基因中，加入顺尔宁孵育24h后检测DDX24蛋白的表达情况。结果如图4所示，图中，Con为阴性对照，MS为顺尔宁，MS-10指作用浓度为10μM，MS-20指作用浓度为20μM。从图中可以看出，顺尔宁能够促进DDX24蛋白的表达。
CysLTR1拮抗剂对DDX24的ATPase酶活性的影响
发明人将孟鲁司特钠及其同类化合物普仑司特、扎鲁司特添加血管内皮细胞中，通过ATPase活性检测实验显示孟鲁司特钠及其同类化合物普仑司特、扎鲁司特抑制DDX24的ATPase酶活性。实验结果如图5所示，图中，Con为阴性对照，MS为顺尔宁，Pra为普仑司 特，Zaf为扎鲁斯特。结果显示孟鲁司特钠及其同类化合物对DDX24的ATPase酶活性有微弱的抑制作用
CysLTR1拮抗剂孟鲁司特钠明显改善脉管血管畸形患者的临床症状
孟鲁司特钠明显改善家族性内脏血管畸形患者的临床症状
发明人将本院收治的内脏脉管畸形患者(属于脉管畸形)随机予以2名患者孟鲁司特钠口服治疗，实验结果如图6所示。其中2名患者CT示胸腹水明显吸收，左右叶肝脏比例无明显异常，下肢水肿、气促明显缓解；1名患者近期孟鲁司特钠治疗后，患者腹胀、气促等症状明显缓解。

Claims (4)

  1. CysLTR1拮抗剂在制备治疗脉管畸形药物中的应用。
  2. 根据权利要求1所述的应用，其特征在于：脉管畸形为DDX24异常表达引起的脉管畸形。
  3. 根据权利要求2所述的应用，其特征在于：脉管畸形包括门静脉狭窄、肝静脉狭窄、肺动脉瓣狭窄、乳糜胸、门脉高压、MOVLD综合征、特发性非硬化性门脉高压征。
  4. 根据权利要求1～3任一项所述的应用，其特征在于：CysLTR1拮抗剂选自孟鲁司特钠、Zafirlukast、Cinalukast、Nedocromil、Pranlukast及其药学上可接受的衍生物。
PCT/CN2020/078296 2019-04-10 2020-03-06 治疗脉管畸形的化合物 WO2020207165A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910283263.0 2019-04-10
CN201910283263 2019-04-10

Publications (1)

Publication Number Publication Date
WO2020207165A1 true WO2020207165A1 (zh) 2020-10-15

Family

ID=68586907

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/078296 WO2020207165A1 (zh) 2019-04-10 2020-03-06 治疗脉管畸形的化合物

Country Status (2)

Country Link
CN (1) CN110496124A (zh)
WO (1) WO2020207165A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115245575A (zh) * 2022-06-14 2022-10-28 中山大学附属第五医院 血管平滑肌细胞特异性ddx24及其下游分子在血管发育中的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110496124A (zh) * 2019-04-10 2019-11-26 中山大学附属第五医院 治疗脉管畸形的化合物
CN111254130B (zh) * 2020-01-20 2021-04-06 中山大学附属第五医院 Ddx24解旋酶点突变抑制肿瘤生长的方法及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052388A1 (en) * 2000-10-30 2002-05-02 Schering Corporation Treatment method
CA2337571C (en) * 2001-02-20 2009-12-22 Asta Medica Aktiengesellschaft Antihistamine leukotriene combinations
EP2738172A1 (en) * 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
CN106456999A (zh) * 2014-02-19 2017-02-22 耶达研究及发展有限公司 用于治疗他汀类药物治疗的副作用的白三烯‑介导的活性的抑制剂
CN108018296A (zh) * 2017-12-13 2018-05-11 中山大学附属第五医院 Ddx24基因突变及其应用
CN108883096A (zh) * 2015-12-17 2018-11-23 林科杰诺米克斯股份有限公司 脉络膜新生血管抑制剂或玻璃膜疣抑制剂及其评价或筛选方法
CN110496124A (zh) * 2019-04-10 2019-11-26 中山大学附属第五医院 治疗脉管畸形的化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3600265A1 (en) * 2017-03-30 2020-02-05 Intelgenx Corp. Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052388A1 (en) * 2000-10-30 2002-05-02 Schering Corporation Treatment method
CA2337571C (en) * 2001-02-20 2009-12-22 Asta Medica Aktiengesellschaft Antihistamine leukotriene combinations
EP2738172A1 (en) * 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
CN106456999A (zh) * 2014-02-19 2017-02-22 耶达研究及发展有限公司 用于治疗他汀类药物治疗的副作用的白三烯‑介导的活性的抑制剂
CN108883096A (zh) * 2015-12-17 2018-11-23 林科杰诺米克斯股份有限公司 脉络膜新生血管抑制剂或玻璃膜疣抑制剂及其评价或筛选方法
CN108018296A (zh) * 2017-12-13 2018-05-11 中山大学附属第五医院 Ddx24基因突变及其应用
CN110496124A (zh) * 2019-04-10 2019-11-26 中山大学附属第五医院 治疗脉管畸形的化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG, CAIJUAN: "FDA Approves Merck's Montelukast Sodium Expanded Indication", MEDICAL ECONOMICS, 9 September 2005 (2005-09-09), DOI: 20200526103217A *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115245575A (zh) * 2022-06-14 2022-10-28 中山大学附属第五医院 血管平滑肌细胞特异性ddx24及其下游分子在血管发育中的应用

Also Published As

Publication number Publication date
CN110496124A (zh) 2019-11-26

Similar Documents

Publication Publication Date Title
WO2020207165A1 (zh) 治疗脉管畸形的化合物
Veauthier et al. Crohn's disease: diagnosis and management
Rocha et al. Fast versus slow progressors of infarct growth in large vessel occlusion stroke: clinical and research implications
Liu et al. The changes of HIF-1α and VEGF expression after TACE in patients with hepatocellular carcinoma
Wataya‐Kaneda et al. Tuberous sclerosis complex: recent advances in manifestations and therapy
Jolly et al. Design and rationale of the TOTAL trial: a randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI
Zhou et al. Zoledronic acid inhibits infiltration of tumor-associated macrophages and angiogenesis following transcatheter arterial chemoembolization in rat hepatocellular carcinoma models
Hu et al. Efficacy and safety of B-mode ultrasound-guided percutaneous transhepatic gallbladder drainage combined with laparoscopic cholecystectomy for acute cholecystitis in elderly and high-risk patients
Wang et al. Renal Denervation Attenuates Adverse Remodeling and Intramyocardial Inflammation in Acute Myocardial Infarction With Ischemia–Reperfusion Injury
Zhang et al. Expert consensus on clinical assessment and intervention of vascular aging in China (2018)
Yasui et al. Multidetector-row computed tomography assessment of adding budesonide/formoterol to tiotropium in patients with chronic obstructive pulmonary disease
Gao et al. Associations between endoscopic primary prophylaxis and rebleeding in liver cirrhosis patients with esophagogastric variceal bleeding
Raina et al. Cardiovascular implications in adolescent and young adult hypertension
Amoo et al. Blood-brain barrier permeability imaging as a predictor for delayed cerebral ischaemia following subarachnoid haemorrhage. A narrative review
Dimitriu-Leen et al. Cardiac 123I-MIBG Imaging beyond Heart Failure Potential Clinical Indications
Di Michele et al. An unusual myocardial infarction
Liu et al. Cerebral collateral circulation as an independent predictor for in-stent restenosis after carotid artery stenting
Blei Update October 2022
Yadav et al. Intralobar pulmonary sequestration in right lower lobe with secondary infection in an adult male
Blei Update April 2023
De Foneska et al. S118 Incidence And Severity Of Chronic Thromboembolic Pulmonary Hypertension Following The Introduction Of A One-stop Clinic For Acute Pulmonary Embolism
Blei Update August 2022
Blei Update October 2020
Wang et al. A case report of successful rescue using veno-arterial extracorporeal membrane oxygenation: managing cerebral-cardiac syndrome
Tong et al. Clinical outcome comparison between transjugular intrahepatic portosystemic shunt and endoscopic treatment in patients with cavernous transformation of the portal vein presenting with variceal bleeding: A retrospective study

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20787477

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20787477

Country of ref document: EP

Kind code of ref document: A1